Short Interest in Apollomics, Inc. (NASDAQ:APLM) Decreases By 50.5%

Apollomics, Inc. (NASDAQ:APLM) was the recipient of a significant drop in short interest in the month of January. As of January 15th, there was short interest totalling 10,800 shares, a drop of 50.5% from the December 31st total of 21,800 shares. Based on an average daily trading volume, of 309,200 shares, the short-interest ratio is presently 0.0 days. Approximately 1.6% of the company’s shares are short sold.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Apollomics stock. Exchange Traded Concepts LLC boosted its stake in Apollomics, Inc. (NASDAQ:APLM) by 247.1% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,259,117 shares of the company’s stock after acquiring an additional 896,316 shares during the quarter. Exchange Traded Concepts LLC owned about 1.41% of Apollomics worth $179,000 at the end of the most recent reporting period. 19.13% of the stock is currently owned by institutional investors.

Apollomics Stock Performance

NASDAQ:APLM opened at $9.11 on Wednesday. The firm’s fifty day simple moving average is $9.64 and its 200 day simple moving average is $12.84. Apollomics has a twelve month low of $6.50 and a twelve month high of $85.00.

About Apollomics

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.